Fig. 2: RPRD1A promoted HCC progression both in vitro and in vivo.
From: RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding
A Western blotting detected the expression of RPRD1A in MHCCLM3 control (NC) and RPRD1A knockdown (shRPRD1A #1 and #2) cells. B Cell proliferation of MHCCLM3 NC and RPRD1A knockdown cells by CCK8 assay. C Western blotting detected the overexpression of RPRD1A by plasmids transfection in MHCCLM3 cells. D Cell proliferation of RPRD1A overexpressed MHCCLM3 cells by CCK8 assay. E–H, (E, G) Representative images and quantification (F, H) of plate colony formation assays in MHCCLM3-NC, MHCCLM3-shRPRD1A, Huh7-NC, Huh7-shRPRD1A, MHCCLM3-vector, MHCCLM3-RPRD1A, Huh7-vector, and Huh7-RPRD1A cells. I-L, (I, K) Representative images and quantification (J, L) of transwell migration assay in MHCCLM3-NC, MHCCLM3-shRPRD1A, Huh7-NC, Huh7-shRPRD1A, MHCCLM3-vector, MHCCLM3-RPRD1A, Huh7-vector and Huh7-RPRD1A cells. M Tumor gross images of MHCCLM3 NC- and shRPRD1A-derived subcutaneous tumors. N Growth curves of MHCCLM3 NC- and shRPRD1A-derived subcutaneous tumors. O Representative images and quantification of lung metastases derived from MHCCLM3 NC and shRPRD1A cells by tail vein injection. Arrows indicated the tumors. P Representative images of tumor pulmonary metastases with hematoxylin & eosin (H&E) and immunohistochemical (IHC) staining. IHC was stained to detect GPC3 and Heppar-1. The p values were determined by a two-tailed t-test. *p < 0.05, **p < 0.01, ***p < 0.001. Results are representative of at least three independent experiments.
